Progenics Stockholders Approve Merger with Lantheus
16 juin 2020 16h05 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find,...
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program
18 mai 2020 08h30 HE
|
Progenics Pharmaceuticals Inc.
- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% -- 63.9% Change in Disease Management Plan Based on PyL Imaging Results -- Planned NDA Submission On Track for Early Third Quarter...
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update
07 mai 2020 07h30 HE
|
Progenics Pharmaceuticals Inc.
Pending Merger with Lantheus Holdings, Inc. for Combination of an Innovative Commercial Life Sciences Company with a Diversified Precision Diagnostics and Radiopharmaceutical Therapeutics...
Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7
23 avr. 2020 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow...
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
13 mars 2020 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top...
Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)
06 févr. 2020 08h30 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review
21 janv. 2020 16h15 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial...
Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting
16 janv. 2020 09h10 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...
Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint
23 déc. 2019 07h00 HE
|
Progenics Pharmaceuticals Inc.
- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance- Company Expects to Submit an NDA to the FDA in the Second Half of 2020- Conference...
Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd
22 déc. 2019 17h00 HE
|
Progenics Pharmaceuticals Inc.
NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and...